Blueprint Medicines Corporation announced AYVAKIT data showing high, durable response rates and prolonged overall survival (OS) in patients with advanced systemic mastocytosis (Advanced SM),...
Blueprint Medicines Corporation announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for...
Analysis Group, a global leader in health economics and outcomes research (HEOR) and regulatory epidemiology, announced that a study it coauthored helped support Blueprint...
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that, effective on April 1, 2022,...
Blueprint Medicines Corporation and Proteovant Therapeutics announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need....
